Ainos (NASDAQ:AIMD) Trading Down 4.9% – What’s Next?

Ainos, Inc. (NASDAQ:AIMD)’s share price traded down 4.9% on Monday . The company traded as low as $1.37 and last traded at $1.37. 34,607 shares changed hands during mid-day trading, an increase of 7% from the average session volume of 32,266 shares. The stock had previously closed at $1.44.

Analyst Ratings Changes

Separately, Weiss Ratings lowered Ainos from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 10th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Ainos has a consensus rating of “Sell”.

Ainos Stock Performance

The company has a market capitalization of $10.30 million, a price-to-earnings ratio of -0.56 and a beta of 2.47. The business’s 50-day simple moving average is $1.51 and its 200-day simple moving average is $1.67.

Ainos (NASDAQ:AIMD) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($0.62) EPS for the quarter. Ainos had a negative return on equity of 217.50% and a negative net margin of 11,912.10%.The business had revenue of $0.15 million for the quarter.

Ainos Company Profile

Ainos, Inc (NASDAQ: AIMD) is a clinical?stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI?401, is an inhaled formulation of ibuprofen in a dry powder format.